Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes

Clinical and Experimental Immunology

Volumn 135, Issue 3, 2004, Pages 497-504

  Schmidt, E ^a   Wehr, B ^a   Tabengwa, E M ^b   Reimer, S ^a   Brocker E B ^a   Zillikens, D ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b University of Alabama at Birmingham   (United States)

Author keywords

Autoimmunity; Blister; Hemidesmosome; mRNA; Pathogenesis; Protease

Indexed keywords

ANTIGEN; AUTOANTIBODY; BP180 ANTIBODY; BULLOUS PEMPHIGOID ANTIGEN 180; IMMUNOGLOBULIN G; MESSENGER RNA; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BLISTER; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMOLYSIS BULLOSA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOSTIMULATION; KERATINOCYTE; PEMPHIGOID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXIC EPIDERMAL NECROLYSIS;

AUTOANTIBODIES; AUTOANTIGENS; CELLS, CULTURED; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOGLOBULIN G; KERATINOCYTES; PEMPHIGOID, BULLOUS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 1542329230     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02401.x     Document Type: Article

References (43)

1. Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI. Characterisation of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 1981; 24:987-1003.
2. Stanley JR, Tanaka T, Mueller S, Klaus-Kortun V, Roop D. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 1988; 82:1864-70.
3. Diaz LA, Ratrie H, Saunders WS, Futamura S, Squiquera HL, Anhalt GJ, Giudice GJ. Isolation of human epidermal cDNA corresponding to the 180-kDa autoantigen recognized by bullous pemphigoid and herpes gestationis sera. J Clin Invest 1990; 86:1088-94.
4. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992; 99:243-50.
5. Tanaka T, Korman NJ, Shimizu H, Eady RAJ, Klaus-Kovtun V, Cehrs K, Stanley JR. Production of rabbit antibodies against carboxyterminal epitopes encoded by bullous pemphigoid cDNA. J Invest Dermatol 1990; 94:617-23.
6. Zillikens D, Giudice GJ. BP180/type XVII collagen: its role in acquired and inherited disorders or the dermal-epidermal junction. Arch Dermatol Res 1999; 291:187-94.
7. Matsumura K, Amagai M, Nishikawa T, Hashimoto T. The majority of bullous pemphigoid and herpes gestationis serum samples react with the NC16a domain of the 180-kDa bullous pemphigoid antigen. Arch Dermatol Res 1996; 288:507-9.
8. Zillikens D, Mascaro JM, Rose PR, Liu Z, Ewing SM, Olague-Marchan M, Diaz LA, Giudice GJ. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997; 109:679-83.
9. Perriard J, Jaunin F, Favre B, Büdinger L, Hertl M, Saurat JH, Borradori L. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. J Invest Dermatol 1999; 112:141-7.
10. Naito K, Morioka S, Ogawa H. The pathogenic mechanisms of blister formation in bullous pemphigoid. J Invest Dermatol 1982; 79:303-6.
11. Gammon WR, Merrit CC, Lewis DM, Sams WMJr., Carlo JR, Wheeler CE Jr. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J Invest Dermatol 1982; 78:285-90.
12. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Giudice GJ. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993; 92:2480-8.
13. Sitaru C, Schmidt E, Petermann S, Munteanu LS, Bröcker EB, Zillikens D. Autoantibodies to BP180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol, 2002; 118:664-71.
14. Schmidt E, Obe K, Bröcker E-B, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol, 2000; 136:174-8.
15. Liu Z, Shipley JM, Vu TH, Zhou X, Diaz LA, Werb Z, Senior RM. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 1998; 188:475-82.
16. Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ, Fairley JA, Diaz LA. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest, 2000; 105:113-23.
17. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, Senior RM, Werb Z. The serpin alphal-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell, 2000; 102:647-55.
18. Liu Z, Chen R, Diaz LA, Senior RM, Werb Z. Plasminogen/plasmin system in experimental bullous pemphigoid. J Invest Dermatol, 2000; 114:778 (Abstract).
19. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth invasion, and metastasis. Cell Mol Life Sci, 2000; 57:25-40.
20. Jensen PJ, John M, Baird J. Urokinase and tissue type plasminogen activators in human keratinocyte culture. Exp Cell Res 1990; 187:162-9.
21. Zillikens D, Kawahara Y, Ishiko A et al. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 1996; 106:1333-8.
22. Balding SD, Diaz LA, Giudice GJ. A recombinant form of the human BP180 ectodomain forms a collagen-like, homotrimeric complex. Biochemistry 1997; 36:8821-30.
23. Kiistala U. Suction blister device for separation of viable epidermis from dermis. J Invest Dermatol 1968; 50:129-37.
24. Schmidt E, Bastian B, Dummer R, Tony HP, Bröcker E-B, Zillikens D. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 1996; 288:353-7.
25. Schmidt E, Reimer S, Kruse N, Jainta S, Bröcker EB, Marinkovich MP, Giudice GJ, Zillikens D. Autoantibodies to BP180 associated with bullous pemphigoid release IL-6 and IL-8 from cultured human keratinocytes. J Invest Dermatol 2000; 115:842-8.
26. Seitz CS, Giudice GJ, Balding SD, Marinkovich MP, Khavari PA. BP180 gene delivery in junctional epidermolysis bullosa. Gene Ther 1999; 6:42-7.
27. Marinkovich MP, Tran HH, Rao SK et al. LAD-1 is absent in a subset of junctional epidermolysis bullosa patients. J Invest Dermatol 1997; 109:356-9.
28. Jones JM, Cohen RL, Chambers DA. Collagen modulates gene activation of plasminogen activator system molecules. Exp Cell Res 2002; 280:244-54.
29. Bator JM, Cohen RL. Chambers DA. Hydrocortisone regulates the dynamics of plasminogen activator and plasminogen activator inhibi-tor expression in cultured murine keratinocytes. Exp Cell Res 1988; 242:110-9.
30. Chen CS, Jensen PJ. Serum is a potent stimulator of keratinocyte tissue plasminogen activator expression. J Invest Dermatol 1996; 106:238-42.
31. Rox JM, Reinartz J, Kramer MD. Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT). Arch Dermatol Res 1996; 288:554-8.
32. Friberger P. Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems. Scand J Clin Laboratory Invest 1982; 162:1-298.
33. Aikens ML, Grenett HE, Benza RL, Tabengwa EM, Davis GC, Booyse FM. Alcohol-induced upregulation of plasminogen activators and fibrinolytic activity in cultured human endothelial cells. Alcohol Clin Exp Res 1998; 22:375-81.
34. Tabengwa EM, Benza RL, Grenett HE, Booyse FM. Hypertriglyceridemic VLDL downregulates tissue plasminogen activator gene transcription through cis-repressive region (s) in the tissue plasminogen activator promoter in cultured human endothelial cells. Arterioscler Thromb Vasc Biol, 2000; 20:1675-81.
35. Kramer MD, Reinartz J. The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin. J Clin Invest 1993; 92:978-83.
36. Gissler HM, Simon MM, Kramer MD. Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid. Br J Dermatol 1992; 127:272-7.
37. Venning VA, Wojnarowska F, Cederholm-Williams S. An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid. Clin Exp Dermatol 1993; 18:119-23.
38. Jensen PJ, Baird J, Morioka S, Lessin S, Lazarus GS. Epidermal plasminogen activator is abnormal in cutaneous lesions. J Invest Dermatol 1988; 90:777-82.
39. Baird J, Lazarus GS, Belin D, Vassalli JD, Busso N, Gubler P. Jensen. mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. J Invest Dermatol 1990; 95:548-52.
40. Stanley JR. Bullous Pemphigoid. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, eds. Dermatology in General Medicine, 5th edn. New York: McGraw-Hill, Inc 1999:666-73.
41. Anhalt GJ, Diaz LA. Research advances in pemphigus. J Am Med Assoc 2001; 285:652-4.
42. Hashimoto K, Shafran KM, Webber PA, Lazarus GS, Singer KH. Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation. J Exp Med 1983; 157:259-72.
43. Mahoney MG, Wang ZH, Stanley JR. Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice. J Invest Dermatol 1999; 113:22-5.